Dr. Reddy's Laboratories Limited (NYSE:RDY - Get Free Report)'s share price gapped down before the market opened on Tuesday . The stock had previously closed at $13.71, but opened at $13.41. Dr. Reddy's Laboratories shares last traded at $13.44, with a volume of 87,686 shares traded.
Wall Street Analyst Weigh In
RDY has been the topic of a number of recent analyst reports. Nomura lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th. StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th.
Check Out Our Latest Analysis on RDY
Dr. Reddy's Laboratories Stock Down 0.6 %
The firm has a 50-day moving average of $13.48 and a two-hundred day moving average of $14.61. The firm has a market cap of $11.01 billion, a price-to-earnings ratio of 21.01 and a beta of 0.48. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, sell-side analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.
Institutional Trading of Dr. Reddy's Laboratories
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC raised its position in shares of Dr. Reddy's Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after buying an additional 1,507 shares during the last quarter. Glass Jacobson Investment Advisors llc increased its stake in Dr. Reddy's Laboratories by 400.0% during the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock valued at $32,000 after acquiring an additional 1,600 shares during the period. POM Investment Strategies LLC raised its holdings in Dr. Reddy's Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after acquiring an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Dr. Reddy's Laboratories by 461.0% in the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after acquiring an additional 2,093 shares during the period. Finally, Allworth Financial LP grew its holdings in shares of Dr. Reddy's Laboratories by 447.8% during the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company's stock worth $41,000 after purchasing an additional 2,230 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Recommended Stories
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
